Download PDF

1. Company Snapshot

1.a. Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests.The company was founded in 2008 and is based in Mainz, Germany.

Show Full description

1.b. Last Insights on MYNZ

Mainz Biomed's recent performance was impacted by a decline in trading volume, with a 68% drop in shares traded. Despite positive developments, including the announcement of a feasibility study for a non-invasive pancreatic cancer screening test and partnerships to expand ColoAlert to South America, concerns may arise from a decrease in investor interest. The company's attendance at conferences, such as MEDICA 2025 and GARPS, may not have provided sufficient momentum. No recent earnings release information is available.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next?

Nov -22

Source: defenseworld.net

Card image cap

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Nov -18

Source: globenewswire.com

Card image cap

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Nov -12

Source: globenewswire.com

Card image cap

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Nov -10

Source: globenewswire.com

Card image cap

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Oct -08

Source: globenewswire.com

Card image cap

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug -13

Source: globenewswire.com

Card image cap

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Aug -04

Source: globenewswire.com

Card image cap

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul -23

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.27%)

6. Segments

Genetic Diagnostic Testing

Expected Growth: 10.27%

Mainz Biomed B.V.'s 10.27% growth in Genetic Diagnostic Testing is driven by increasing demand for non-invasive cancer diagnostics, advancements in genetic sequencing technologies, and growing adoption in emerging markets. Additionally, rising incidence of cancer and genetic disorders, coupled with government initiatives to promote early disease detection, are fueling growth in this segment.

7. Detailed Products

Colorectal Cancer Screening Test

A non-invasive, stool-based DNA test for the early detection of colorectal cancer

Colorectal Cancer Recurrence Test

A blood-based test for the detection of circulating tumor DNA in patients with a history of colorectal cancer

CRC-Protect

A blood-based test for the detection of methylated Septin 9, a biomarker for colorectal cancer

8. Mainz Biomed B.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Mainz Biomed B.V. is medium due to the availability of alternative diagnostic tests and treatments for cancer.

Bargaining Power Of Customers

The bargaining power of customers for Mainz Biomed B.V. is low due to the specialized nature of the company's products and services.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Mainz Biomed B.V. is medium due to the availability of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

The threat of new entrants for Mainz Biomed B.V. is high due to the growing demand for cancer diagnostics and the potential for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry for Mainz Biomed B.V. is high due to the competitive nature of the cancer diagnostics market and the presence of established companies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 69.55%
Debt Cost 5.35%
Equity Weight 30.45%
Equity Cost 5.35%
WACC 5.35%
Leverage 228.39%

11. Quality Control: Mainz Biomed B.V. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Lumibird

A-Score: 3.7/10

Value: 2.3

Growth: 5.4

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Centogene

A-Score: 3.5/10

Value: 10.0

Growth: 1.4

Quality: 5.5

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Moolec Science

A-Score: 3.1/10

Value: 7.8

Growth: 3.3

Quality: 2.5

Yield: 0.0

Momentum: 5.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Vimian Group

A-Score: 2.9/10

Value: 2.1

Growth: 7.2

Quality: 5.5

Yield: 0.0

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Mainz Biomed

A-Score: 2.6/10

Value: 8.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Selvita

A-Score: 2.3/10

Value: 3.5

Growth: 4.9

Quality: 3.7

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.16$

Current Price

1.16$

Potential

-0.00%

Expected Cash-Flows